ArticleGE Portuguese journal of gastroenterology2025
Severe Recurrent Gastrointestinal Bleeding and Diagnostic Dilemmas in Zollinger-Ellison Syndrome: A Case Report.
Article in GE Portuguese journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zollinger-Ellison Syndrome (ZES) is a rare condition caused by gastrin-secreting neuroendocrine tumours (gastrinoma) that induce excessive gastric acid production, leading to severe peptic ulcer disease (PUD) and gastrointestinal (GI) complications. Its nonspecific presentation often delays diagnosis, increasing the risk of life-threatening outcomes. We report the case of a 53-year-old man with chronic gastroesophageal reflux disease and long-standing unexplored diarrhoea who presented with worsening abdominal pain and severe diarrhoea. Laboratory tests showed acute kidney injury, and CT revealed gastric wall thickening and a hyperdense nodule at the gastroduodenal junction, raising suspicion for ZES. Despite proton pump inhibitor (PPI) therapy, he developed recurrent upper GI bleeding requiring intensive care unit admission. Hormonal and imaging studies confirmed ZES, and he underwent antrectomy with lymphadenectomy. Postoperatively, he experienced further GI bleeding managed with over-the-scope clip (OTSC®) haemostasis and gastroduodenal artery ligation. Pathology confirmed a well-differentiated neuroendocrine tumour (pT2N1, G1). One year later, he remained asymptomatic with no evidence of recurrence. This case illustrates the diagnostic and therapeutic challenges of ZES, underscoring the risks associated with PPI withdrawal during evaluation and the need for multidisciplinary management. Recurrent GI bleeding in ZES requires a coordinated approach integrating medical, endoscopic, and surgical therapies. Early recognition is essential to prevent severe complications, and a high index of suspicion is warranted in patients with refractory PUD, chronic diarrhoea, or unexplained GI bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.